Introduction
The non-receptor tyrosine kinase c-Src is over-expressed and activated in a large number of human malignancies and has been linked to the development of cancer and progression to distant metastases (reviewed in Martin, 2001; Frame, 2002; Yeatman, 2004) . The cognate oncogenic kinase v-Src efficiently transforms a wide range of cells in culture as well as primary cells (reviewed in Thomas and Brugge, 1997) . Transformation by v-Src most likely results from the constitutive activation of the same pathways that are modulated by c-Src in normal cells. Therefore, information obtained from studies on v-Src transformation in vitro can shed light on the role of c-Src in cancer (Martin, 2001; Frame, 2002; Yeatman, 2004) . Expression of an activated Src leads to a variety of phenotypic changes, including morphological transformation and acquisition of anchorage and growth factor independence for proliferation, and in tumorigenicity in vivo (Thomas and Brugge, 1997; Frame, 2002) . These transformation traits result from v-Src activating numerous signalling molecules involved in regulation of actin cytoskeleton, cell adhesion and migration and in control of cell proliferation and survival (Martin, 2001; Parsons and Parsons, 2004) . Among these molecules, the Ras GTPase, the phosphatidylinositol 3-kinase (PI3K), the STAT family of transcription factors and their downstream effectors are found activated in different cell settings transformed by v-Src, although their relative contribution to transformation may vary depending on the cell type (Penuel and Martin, 1999; Nguyen et al., 2000; Odajima et al., 2000) .
A long-standing issue concerning transformation by retroviral oncogenes is host dependency, attributed to differences in oncoprotein expression levels and/or activity, or to specific factors whose expression varies in different cell types or species (Verderame et al., 1989; Falcone et al., 1992; Li et al., 1996) . An alternative hypothesis sees oncoprotein host dependency deriving from a requirement for activation of multiple downstream pathways. In some cell species, certain pathways may be constitutively active and thus activation of a single pathway will be sufficient for transformation; in other cell contexts, multiple pathways have to be activated for transformation (Li et al., 1996) . Hostdependent differences concerning the role of the RasRaf-MAPK kinase (MEK) pathway in v-Src-induced transformation have also been reported. Specifically, whereas Ras-Raf interaction and MEK activation appeared necessary and sufficient for transformation of mammalian fibroblasts by v-Src (Smith et al., 1986; Cowley et al., 1994; Marais et al., 1995) , in chicken fibroblasts Ras activation was found not necessary for v-Src-induced transformation (Aftab et al., 1997) , although the Ras-MEK and the PI3K-mTor pathways both contributed to transformation (Penuel and Martin, 1999) .
Besides the derangement of growth control, transformation by v-Src usually entails inhibition of differentiation (reviewed by Olson, 1992; Alema`and Tato`, 1994; Thomas and Brugge, 1997) . For example, myogenic cells, a prototypic model cell system for in vitro differentiation, are prevented to undergo terminal differentiation when transformed by oncoproteins including v-Src (Olson, 1992; Alema`and Tato`, 1994) that interfere with the expression and/or the activity of myogenic regulatory factors (MRFs) (Lassar et al., 1989; Russo et al., 1997; Perry et al., 2001; Falcone et al., 2003) . However, the signalling pathways that lead to inhibition of MRFs function have remained largely obscure. Earlier work showed that primary avian myoblasts transformed by a conditional v-Src kinase are extremely well suited to study all facets of the transformed phenotype, such as control of proliferation (Falcone et al., 2003) , block of differentiation (Falcone et al., 2003) and alterations of myofibrillar assembly in myocytes (Castellani et al., 1995; Gallo et al., 1999) . We have previously established that v-Src affects the expression of muscle-specific genes in quail myoblasts independently of the effects on the cell cycle (Falcone et al., 2003) . Thus, the necessity arises of identifying the signalling pathways involved in transformation and/or in block of myogenesis. Since more than one signalling pathways may be activated simultaneously by v-Src, in order to assign the specific contribution of an individual pathway to each transformation trait, we utilized the experimental approach of interfering with individual pathways.
We show here that (1) Ras and its downstream pathways MEK-extracellular signal-regulated kinase (ERK) and PI3K play a central role both in loss of growth control of v-Src-transformed avian fibroblasts and myoblasts, and in inhibition of differentiation in v-Src myoblasts; (2) via the MEK pathway v-Src also inhibits activation of p38 MAPK (p38), which is essential for muscle-specific gene expression (Puri and Sartorelli, 2000; Keren et al., 2006; Lluis et al., 2006) and (3) the simultaneous modulation of only three pathways, the Ras-MEK, the p38 and the calpain pathways, appears sufficient to account for block of muscle-specific gene expression by v-Src.
Results
Ras and PI3 kinase pathways are crucial to v-Src-induced growth factor-and anchorage-independent proliferation Proliferation of v-Src-transformed murine cells requires Ras-controlled signalling pathways (Smith et al., 1986; Cowley et al., 1994) . In v-Src-transformed avian fibroblasts, however, Ras pathway does not seem to be required (Penuel and Martin, 1999) . To clarify this apparent species-specific difference, we investigated the role of Ras in the proliferation of primary chicken embryos fibroblasts (CEF) and v-Src-transformed CEF and quail myoblasts. Two distinct approaches were used to inhibit Ras functions: microinjection of the neutralizing monoclonal antibody (mAb) Y13-259, known to interfere with the Ras nucleotide exchange reaction (Hattori et al., 1987) , and forced expression of RasN17, a dominant-negative mutant form of Ras that acts by sequestering endogenous guanine nucleotide exchange factors (GEFs) (Boguski and McCormick, 1993) . Parental CEF and CEF infected with the SchmidtRuppin strain of Rous sarcoma virus (RSV, CEF-SR-D), kept in low serum for 24 h, were microinjected with mAb Y13-259. The rate of proliferation was evaluated in CEF stimulated with 10% fetal calf serum (FCS) and in CEF-SR-D kept in 0.5% FCS by measuring the number of cells that had incorporated bromodeoxyuridine (BrdU) over a period of 20 h. An inhibition of about 80% was measured both in parental CEF and CEF-SR-D microinjected with mAb Y13-259 ( Figure 1a ). Inhibition of Ras activity was also achieved by transient transfection of CEF-SR-D and quail myoblasts transformed by a temperature-sensitive mutant of v-Src (QMb-LA29) at the permissive temperature (351C) with an expression vector for RasN17. BrdU incorporation of RasN17 expressing-cells kept in 0.5% FCS evidenced a 90% inhibition of proliferation compared to that of cells expressing b-galactosidase (b-gal), used as control (Figures 1a and b) . Together, the two approaches allow to conclude that the Ras GTPase plays a pivotal role in controlling proliferation of both normal and v-Srctransformed avian cells.
The contribution of distinct signalling pathways to the v-Src-induced growth factor-independent proliferation was evaluated by using specific pharmacological inhibitors or forced expression of dominant-negative mutant molecules. Specifically, QMb-LA29 were treated at 351C in low serum medium either with inhibitors of the upstream ERK activator MEK, PD98059 and U0126, or the p38 inhibitor SB203580 or the PI3K inhibitor LY294002. The Src family kinase inhibitor herbimycin A was used as control. The activity of PI3K was also inhibited by transfecting cells with an expression vector for p85DiSH2-N (Rodriguez-Viciana et al., 1997), a dominant-negative mutant of PI3K. To verify the specificity of the inhibitors, parallel cultures were analysed for total phospho-tyrosine content by western blot and found to display levels of tyrosine-phosphorylated proteins comparable to those of untreated control (not shown). Treatment of QMb-LA29 with PD98059 or U0126 resulted in about 50% inhibition of serumindependent proliferation, as assessed by BrdU incorporation, while inhibition of PI3K with LY294002 or by forced expression of the p85DiSH2-N mutant induced a 30% inhibition (Figure 1b) . The combined use of U0126 and LY294002 blocked proliferation almost completely, suggesting that the MEK and PI3K pathways are sufficient to support v-Src-induced cell growth. Treatment with herbimycin A led to an 80% inhibition, whereas no effect was observed with the p38 inhibitor SB203580 (Figure 1a ). To rule out that the observed decrease in growth rate could be due to apoptosis, flow cytometric analysis of subconfuent cultures treated with Signalling pathways in v-Src myoblasts L Ciuffini et al herbimycin A, U0126 or LY249002 alone or in combination was performed. No significant differences in the percentage of apoptotic cells (o4.0%) were found between treated and untreated cells (data not shown).
To define the contribution of the MEK, PI3K and p38 signalling pathways in the anchorage-independent growth of v-Src-transformed cells, QMb-LA29 were plated in semisolid medium in the presence of U0126, LY294002, SB203580 and herbimycin A, and allowed to grow for 2 weeks. Both number and size of the colonies were evaluated. Based on size, colonies were classified as 'small' (diameter between 0.1 and 0.25 mm) and 'large' (diameter larger than 0.25 mm). A reduction of about 50% in the total number of colonies was observed with either U0126 or LY294002 compared to control, although with different efficiency on small and large colonies: treatment with U0126 reduced both small and large colonies, while that with LY294002 slightly increased the number of small colonies but drastically reduced the number of large colonies (Figure 1c ). This may reflect a specific requirement of the PI3K pathway for autocrine growth factor production that sustains the formation of large colonies. Inhibition of p38 activity by SB203580 had no effect on colonies formation while the presence of herbimycin A radically reduced the number of colonies (Figure 1c) . No colonies were observed in QMb-LA29 kept at the restrictive temperature for v-Src (411C). Taken together, these results indicate that the Ras-MEK and the PI3K pathways are both crucial in v-Src-induced growth transformation.
Ras-MEK-ERK pathway is activated in v-Src myoblasts and contributes to block of differentiation independently of cell proliferation Transformation by v-Src of specific cell lineages, including myogenic cells, is often associated with block of differentiation. Having established that Ras is involved in v-Src-induced growth alterations, we examined whether the Ras-MEK pathway is also directly implicated in the inhibition of v-Src-transformed myoblasts differentiation. We first measured Ras and ERK activation levels in QMb-LA29, maintained proliferating at 351C or differentiated at 411C for 2 days (Figure 2a ). Higher levels of GTP-bound Ras were found in myoblasts kept at 351C compared to myotubes at 411C, where active Ras was almost undetectable. Ras activity was restored in myotubes by shifting the cultures to 351 (Figure 2a) . Consistently, the levels of phosphorylated and therefore active ERK (pERK) decreased in myotubes at 411C, compared to myoblasts at 351C, and were readily resumed in myotubes following v-Src activation by temperature shift (Figure 2b ). Note that low levels of pERK persisted at 411C, possibly due to a specific function of this kinase in myotubes (Wu et al., 2000) .
To investigate whether the Ras pathway was responsible for the v-Src-dependent block of myoblast differentiation, we interfered with the Ras signalling pathway by different means. First, QMb-LA29 were transfected with an expression vector for RasN17 at 351C and myogenic differentiation was evaluated in transfected cells by immunofluorescence. We found that about 50% of the cells expressing RasN17 acquired the ability to accumulate muscle-specific proteins such as myogenin Signalling pathways in v-Src myoblasts L Ciuffini et al and myosin (Table 1 ). The ability of RasN17 of relieving the v-Src-dependent block of differentiation was also investigated in the entire cell population by infecting QMb-LA29 with recombinant adenoviruses encoding for RasN17 (adeno-RasN17) or b-gal (adeno-b-gal), as control. Infected myoblasts were allowed to express the transgene for 2 days at 351C, and then analysed by western blot. Accumulation of muscle-specific a-actinin, myosin, calsequestrin and a-actin was observed in v-Srctransformed cells expressing RasN17 compared to cells expressing b-gal, though at lower levels than in differentiated myotubes at 411C (Figure 2c ). Altogether, these findings demonstrate that the block imposed by v-Src on muscle differentiation can be partially relieved by inhibiting Ras activity. Notably, RhoA and Rac1, members of the Ras family of small GTPases, partially sustain v-Src-induced inhibition of differentiation since forced expression of dominant-negative mutants of RhoA or Rac1 increased the number of myogeninpositive cells (Table 1) . The contribution of MEK signalling in v-Src-dependent inhibition of differentiation was investigated by using the specific MEK inhibitors PD98059 and U0126. QMb-LA29 treated with PD98059 or U0126 at 351C and processed for immunofluorescence showed a large increase in the number of cells expressing myogenin and myosin (Table 1) . Consistently, accumulation of musclespecific proteins was also increased (Figure 2d ), clearly Signalling pathways in v-Src myoblasts L Ciuffini et al indicating that inhibition of MEK activity promoted differentiation of v-Src-transformed myoblasts. We had previously shown that forced expression of the cdk inhibitor p27 causes QMb-LA29 to exit from the cell cycle, yet does not promote myogenic differentiation (Falcone et al., 2003) . To determine whether the MEK pathway is directly involved in the v-Src block of differentiation or acts by keeping cells proliferating (Figure 1b) , we infected QMb-LA29 with adenoviruses encoding for p27 and b-gal and, after 24 h, added PD98059 or U0126 to the culture medium for 2 days. As shown in Figure 2e , myoblasts expressing p27 exhibited a 90% inhibition of proliferation compared with b-galexpressing myoblasts. Moreover, expression of myogenin and a-actinin was comparably induced by U0126 or PD98059 in myoblasts either expressing p27 or b-gal, indicating that inhibition of MEK relieves the block of differentiation in v-Src-transformed myoblasts independently of their proliferative state.
Given the role of the PI3K pathway in v-Src-induced proliferation (Figures 1b and c ; Penuel and Martin, 1999, Nguyen et al., 2000) , we asked whether PI3K could also be involved in block of differentiation. This is a complex issue, however, since PI3K is known to play a positive role in myogenic differentiation and its inhibition impairs the expression of muscle-specific genes (Jiang et al., 1998; Tureckova et al., 2001) . Indeed, treatment of QMb-LA29 at 351C with the PI3K inhibitor LY294002 did not induce expression of myogenin (Table 1 and Figure 2d ) indicating that the PI3K pathway does not participate in v-Src-induced block of myogenic differentiation. Moreover, LY294002 did not affect the U0126-induced accumulation of the early myogenic marker myogenin in QMb-LA29 at 351C, but diminished that of contractile proteins such as a-actinin (Figure 2d) , consistently with the trophic role played by PI3K in myotubes (Jiang et al., 1998) .
v-Src blocks differentiation by downregulating p38 activation Since p38 is required during myogenic differentiation (reviewed in Puri and Sartorelli, 2000; Lluis et al., 2006) and its inhibition by SB203580 does not affect growth factor-and anchorage-independent proliferation of QMb-LA29 (Figures 1b and c) , we investigated whether one mechanism by which v-Src inhibits muscle differentiation is by preventing p38 phosphorylation, and therefore its activation. Indeed, accumulation of phosphorylated p38 (pp38) was undetectable in QMb-LA29 maintained at 351C in growth medium (GM) and very low in differentiation medium (DM), but significantly increased following UV-light irradiation indicating that p38 activity can be modulated in these cells (Figure 3a) . The high levels of pp38 observed in differentiated myotubes at 411C were reduced following v-Src activation ( Figure 3a) . Therefore, QMb-LA29 were transfected at 351C in DM with expression vectors for MKK6EE, a constitutively active mutant of the p38 upstream activator MKK6 (Raingeaud et al., 1996) . As shown in Figure 1a , activation of p38 by MKK6EE resulted in a significant inhibition of QMb-LA29 proliferation. This finding correlates with a recent report showing that p38 activation is elevated in non-transformed growtharrested fibroblasts and is required for contact inhibition (Faust et al., 2005) .
To measure whether forced activation of p38 resulted in muscle-specific transcriptional activation, QMb-LA29 were transfected with expression vectors for MKK6EE or green fluorescent protein (GFP) along with chloramphenicol acetyltransferase (CAT) reporter constructs driven by the muscle-specific muscle creatine kinase (MCK) promoter or by the constitutive RSV promoter as control. Expression of MKK6EE in DM at 351 induced transcription from the MCK promoter to levels comparable to those measured at 411C, and such transcription was abolished by treatment with the p38 inhibitor SB203580 (Figure 3b ). Parallel plates expressing MKK6EE or b-gal were processed by immunofluorescence and scored for accumulation for either myogenin or myosin. As shown in Figure 3c , accumulation of both proteins was observed in MKK6EE-positive cells and inhibited by SB203580 treatment. Consistently, QMb-LA29 infected with an adenovirus expressing MKK6EE (adeno-MKK6EE) and assayed for accumulation of muscle-specific proteins by western blot showed increased accumulation of myosin and myogenin accompanied by an increase in pp38 and p27 content, compared with adeno-b-gal-infected myoblasts (Figure 3d ). Note that SB203580 specifically inhibited p27 accumulation both in control and MKK6EE-infected cells (Figure 3d ), suggesting that p38 might have a role in p27 regulation. Together, these results indicate that v-Src promotes growth factor-independent proliferation and inhibits myogenic differentiation via the downregulation of p38.
The finding that either inhibition of the Ras-MEK pathway or activation of p38 restored, at least in part, myogenic differentiation of v-Src-transformed myoblasts, suggested that there could be a cross-regulation Signalling pathways in v-Src myoblasts L Ciuffini et al between the two signalling pathways. To test this hypothesis, QMb-LA29 at 351C in DM were treated with U0126 and SB203580, separately or in combination, and analysed for pERK, pp38 and muscle-specific proteins accumulation by western blot. As shown in Figure 4a , U0126 inhibited ERK phosphorylation, induced accumulation of muscle-specific proteins such as myogenin and a-actinin, and promoted a moderate, albeit consistent increase in pp38 levels. SB203580, instead, increased pERK without inducing musclespecific gene expression. Note that SB203580 induced an increase in the levels of pp38, probably through the inhibition of a self-regulatory loop mediated by a p38-activated protein phosphatase 2A (Sundaresan and Farndale, 2002) . Indeed, treatment of QMb-LA29 in DM at 351C with okadaic acid (100 nM), a specific inhibitor of protein phosphatase 2A, induced a significant increase in the level of p38 phosphorylation (not shown). When SB203580 was used in combination with U0126, the levels of pERK were increased and the accumulation of muscle-specific proteins diminished, compared to those measured in U0126-treated cells (Figure 4a ). In addition, a further increase in the levels of pp38 was observed, compared to the levels induced by the two inhibitors used separately (Figure 4a ). We further investigated the putative upstream role of Ras as a negative regulator of p38 activation. Adeno-RasN17-and adeno-b-galinfected QMb-LA29 were maintained in DM at 351C for 2 days, before being analysed by western blot for accumulation of pERK, pp38 and muscle-specific proteins. Adeno-b-gal-infected QMb-LA29 were also induced to differentiate at 411C. As shown in Figure 4b , myoblasts expressing RasN17 showed inhibition of pERK and induction of a-actinin, whereas pp38 was increased to levels comparable to those observed in fully differentiated cells at 411C (Figure 4b ). These results show that the activity of p38 is negatively regulated by the Ras-MEK pathway, and, conversely, that p38 function leads to inhibition of ERK phosphorylation and plays a crucial role in myogenic differentiation. 
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Inhibition of Ras-MEK partially recovers phenotypical skeletal muscle differentiation Inactivation of v-Src by shift of QMb-LA29 to 411C results in the initiation of the differentiation program, characterized by accumulation of muscle-specific proteins, fusion into myotubes and assembly of highly ordered myofibrils ( Figure 5 ). To determine whether the inhibition of the Ras-MEK pathway or the activation of p38 in QMb-LA29 at 351C not only promoted accumulation of muscle-specific markers, but also induced fusion and sarcomere organization, myoblasts infected with adeno-RasN17 or adeno-MKK6EE or treated with U0126 were kept in DM at 351C for up to 4 days and processed for immunofluorescence. As shown in Figure 5 , cells expressing RasN17 or treated with U0126 were found to fuse into atypical myotubes with clustered nuclei displaying a cross-striated pattern due to myosin assembly in sarcomeres. In contrast, cells expressing adeno-MKK6EE, although polynucleated, displayed a fibre-like staining for myosin, without a detectable specific pattern. Control cells, infected with adeno-GFP or treated with dimethyl sulfoxide (DMSO), only occasionally showed myosin-positive cells, while cells treated with herbimycin A at 351 or maintained at 411C fused into polynucleated myotubes characterized by a pronounced cross-striated myosin pattern ( Figure 5 ). Altogether these data indicate that the block of differentiation operated by v-Src acts through distinct pathways that inhibit muscle-specific gene expression and that alter the formation of specialized macromolecular assembly such as sarcomeres. Indeed, inhibition of the Ras-MEK pathway partly recovers both aspects of myogenic differentiation, while activation of p38 is insufficient to promote sarcomere assembly, highlighting that these pathways impinge on distinct effectors.
Combined inhibition of MEK and calpain, and activation of p38 restore the differentiation potential of v-Src myoblasts Transformation by v-Src entails activation of the calpain proteolytic activity (Carragher and Frame, 2002) . To investigate whether block of differentiation by v-Src also requires calpain activity, QMb-LA29 at 351C in DM were treated with the specific calpain inhibitor N-acetyl-Leu-Leu-Met (ALLM) (12.5 mM) and analysed for accumulation of muscle-specific proteins by western blot and immunofluorescence. Addition of ALLM did not significantly affect cell proliferation and morphology (not shown), and induced only a slight increase in the accumulation of myogenin and p27 compared to control cells ( Figure 6 ). Higher ALLM concentrations (25 mM) significantly increased the number of cells expressing myogenin, but also inhibited cell proliferation and reduced total levels of tyrosinephosphorylated proteins (not shown). Based on this finding, we used ALLM in combination with U0126 at the concentration that was not growth inhibitory in order to measure the contribution of the calpain and the MEK pathways to the block of differentiation. As shown in Figure 6 , the combined treatment of myoblasts with ALLM and U0126 increased the accumulation of p27, a-actinin and myogenin to levels comparable to those observed following treatment with herbimycin A (Figure 6 ), clearly indicating that both calpain and MEK independently contribute to the block of differentiation operated by v-Src. The induction of calpain activity in myoblasts appears to be specifically due to Figure 5 Phenotype of v-Src-transformed myoblasts induced to differentiate by Ras-MEK inhibitors or p38 activators. Representative immunofluorescence micrographs of QMb-LA29 infected with adenoviruses expressing RasN17 (Ad-RasN17) or MKK6EE (Ad-MKK6EE) or treated with U0126, herbimycin A or DMSO and stained for muscle-specific myosin (shown in red). Nuclei were stained with Hoechst 33258 (shown in blue). Scale bar: 20 mM.
Signalling pathways in v-Src myoblasts L Ciuffini et al v-Src, since treatment of primary quail myoblasts with ALLM did not promote accumulation of musclespecific proteins in growth factor-containing medium (not shown).
Having shown that activation of p38 and inhibition of the Ras-MEK and calpain signalling pathways all contributed to recover differentiation of v-Src-transformed myoblasts, we attempted to fully reconstitute commitment of QMb-LA29 to terminal differentiation by modulating the three pathways at the same time. To this aim, myoblasts were infected with adeno-MKK6EE at 351C and, 1 day later, treated with ALLM and U0126 separately or in combination for additional 2 days. Cells were then processed by immunofluorescence and scored for myogenin and a-actinin. As shown in Figure 6 , the combined inhibition of MEK and calpain and activation of p38 resulted in a number of differentiated cells comparable to that observed at 411C, clearly showing that modulation of these three pathways by v-Src is sufficient for inhibition of myogenic differentiation.
Discussion
Transformation of skeletal myoblasts by v-Src tyrosine kinase results in growth factor-and anchorage-independent proliferation and in inhibition of terminal differentiation. Although exit from the cell cycle and commitment to differentiation are necessarily linked processes, inhibition of myogenesis by v-Src in both avian and murine myoblasts can occur independently of cell proliferation (Falcone et al., 2003) . In myocytes, v-Src negatively affects transcription of muscle-specific genes by targeting the function of MRFs, in part by interfering with their interaction with co-regulators that control chromatin remodelling (Falcone et al., 2003) . However, the cytoplasmic pathways activated by v-Src that convey the inhibitory signals from the cell periphery to the nucleus, eventually leading to block of musclespecific transcription, have not yet been defined. Therefore, it appears necessary to identify these pathways and to assess whether the same pathways responsible for derangement of proliferation are also involved in block of differentiation.
In this study, we show that primary fibroblasts and myoblasts expressing v-Src acquire all major traits of transformation in a strictly Ras-dependent manner. Downstream of Ras, both MEK and PI3K pathways seem to be required for growth factor-independent proliferation, whereas the PI3K pathway appears primarily involved in sustaining anchorage-independent growth (Figure 7) . In mammalian fibroblasts, Ras-Raf Signalling pathways in v-Src myoblasts L Ciuffini et al interaction and MEK activation were also shown to be necessary and sufficient for growth transformation by v-Src (Smith et al., 1986; Cowley et al., 1994; Marais et al., 1995) . In CEF, however, it was reported that Ras activation was not sufficient for v-Src-induced transformation (Aftab et al., 1997) , pointing out a possible hostdependent specificity. This apparent discrepancy can be explained by surmising that in the experiments described in Aftab et al. (1997) , the expression level of the dominant-negative mutant RasN17 was not sufficient to inhibit Ras signalling in cells expressing v-Src. Here, Ras function was inhibited by either over-expression of RasN17 or microinjection of Ras-neutralizing antibodies and, in both instances, we observed inhibition of v-Src-induced DNA synthesis, perhaps because of a more efficient inhibition of the interaction of Ras with its upstream regulators and downstream effectors (Hattori et al., 1987) . The role of PI3K was previously described in CEFs and in mammalian cells transformed by v-Src, and found to contribute to the specific transformation-associated properties of these cells albeit to a different extent (Penuel and Martin, 1999; Nguyen et al., 2000; Odajima et al., 2000) . In addition, a viral oncogene derived from the catalytic subunit of PI3K can transform CEFs efficiently (Chang et al., 1997) . Although PI3K is a major Ras downstream effector, it is possible that PI3K is activated in Src-transformed myoblasts independently of Ras, for instance by direct phosphorylation of the p85 regulatory subunit (Penuel and Martin, 1999; Odajima et al., 2000) .
Besides the crucial role played in v-Src-dependent control of proliferation, we find here that the Ras-MEK pathway is a major determinant of v-Src-induced block of differentiation. Indeed, expression of muscle-specific genes, fusion into multinucleated myotubes and formation of specialized contractile structures are all readily induced in v-Src myoblasts upon expression of RasN17 or exposure to specific MEK inhibitors. Moreover, we also show that inhibition of MEK relieves the block of differentiation independently of the proliferative state of the cells, suggesting that the Ras-MEK pathway is directly involved in modulating MRF activity. The involvement of the Ras-Raf-MEK pathway in myogenic differentiation has been previously investigated. While ectopic expression of oncogenic Ras, and of constitutively active Raf and MEK kinases have been reported to inhibit myogenesis in myoblasts from different species (Russo et al., 1997; Weyman et al., 1997; Dorman and Johnson, 1999; Perry et al., 2001; Castellani et al., 2006) , discrepant results were described concerning the role of endogenous Ras-MEK pathway. In C2C12 myoblasts, MEK was reported to inhibit differentiation (Wu et al., 2000; Perry et al., 2001) or to play a positive role or no role at all in myogenesis (Gredinger et al., 1998; Cuenda and Cohen, 1999) . Interestingly, the ERK pathway was suggested to play either a positive or a negative role in myogenesis, depending on the differentiation stage (Bennett and Tonks, 1997; Wu et al., 2000) .
The PI3K pathway is known to play a positive role on myogenic differentiation of both murine and chicken myoblasts (Jiang et al., 1998; Tureckova et al., 2001) . Consistently, inhibition of PI3K impairs the full expression of muscle-specific genes in primary quail myocytes and, conversely, ectopic expression of an activated PI3K allele induces the formation of hypertrophic myotubes (our unpublished results). Therefore, it is not surprising that inhibition of PI3K in v-Src myoblasts does not induce the expression of musclespecific proteins, indicating that this pathway only contributes to v-Src-induced proliferation and not to block myogenic differentiation (Figure 7) .
Perhaps the most interesting finding of this work is the identification of the p38 pathway, whose role in promoting myogenesis is well established (Puri and Sartorelli, 2000; Keren et al., 2006; Lluis et al., 2006) , as a critical target of a transforming oncogene such as v-Src in both control of proliferation and block of differentiation. Consistent with its downregulation, forced activation of p38 by over-expression of the upstream activator MKK6EE in v-Src-transformed myoblasts inhibits proliferation and induces terminal Figure 7 Schematic model for the pathways modulated by v-Src in transformed myoblasts. Upon expression of v-Src in primary myoblasts and ensuing activation of Ras, signals are propagated downstream along the Ras-MEK-ERK pathway, which plays a pivotal role in control of unrestrained cell growth. The Ras-MEK-ERK is also crucial in proliferation-independent block of musclespecific gene expression. The activation and integrity of the PI3K pathway appears to be critical role only in controlling unrestrained proliferation. Interestingly, the Ras-MEK pathway is responsible for inhibiting activation of p38, essential for expression of musclespecific genes in normal myoblasts, although a direct inhibition of upstream activators of p38 by v-Src cannot be excluded. Conversely, p38 can act as a modulator of ERK output, suggesting the existence of a regulatory loop assisting expression of differentiation. It appears that, in order to fully inhibit differentiation, v-Src also impinges on activation of a calpain-controlled pathway.
Signalling pathways in v-Src myoblasts L Ciuffini et al differentiation. Expression of MKK6EE in myoblasts growth arrested by either ectopic expression of p27 or mitomycin C treatment induces differentiation at the same level as in untreated cells, further stressing that the impairment of muscle-specific gene expression in v-Srctransformed myoblasts is independent of loss of control of proliferation (unpublished results). Also intriguing is the observation that in this myogenic context, the Ras-MEK pathway negatively regulates the activation of p38 MAPK and, conversely, that p38 activity leads to inhibition of ERK activation, suggesting the existence of a regulatory loop assisting in the execution of the differentiation program. On the one hand, the combined inhibition of MEK and activation of p38 results in the additive induction of differentiation at the single cell level (see Figure 6 ), suggesting that the two pathways may be modulated by v-Src independently. On the other hand, a sizeable proportion of differentiation recovered by direct inhibition of MEK appears to be dependent on p38 function, suggesting that MEK controls block of differentiation by influencing activation of ERK and inhibition of p38 ( Figure 7) . We have previously shown that v-Src blocks myogenic differentiation by inhibiting MRFs transcriptional activation and by interfering with their interaction with co-regulators that control chromatin remodelling (Falcone et al., 2003) . p38 has been shown to induce transcription at myogenic loci by promoting the formation of MyoD-E47 functional heterodimers as well as the recruitment of chromatin remodelling SWI/ SNF activity (reviewed in Lluis et al., 2006) . Therefore, it is likely that v-Src inhibits transcription of musclespecific genes by preventing p38 crucial modulation of transcription. Although not proved, the possibility holds for a direct effect of MEK-ERK on expression of muscle-specific genes upon their transfer to the nucleus (Castellani et al., 1995; Perry et al., 2001) .
It has to be noted that QMb-LA29 differentiated at the permissive temperature upon inhibition of the Ras-MEK pathway do not reach a degree of differentiation comparable to that observed at the restrictive temperature implying that other pathways, altered by v-Src, probably regulate other aspects of the differentiation program such as fusion into long multinucleated myotubes and assembly and maturation of the contractile apparatus. In particular, ectopic expression of MKK6EE, while inducing expression of muscle-specific proteins and fusion into myotubes, did not promote sarcomere assembly. The inability of myotubes expressing MKK6EE to undergo full phenotypic differentiation can be correlated with a recently reported negative role of p38 at late differentiation stages (Lluis et al., 2006) . Among the pathways possibly involved in inhibition of these traits of differentiation, the Rac1 and RhoA GTPases are likely to play a role, since we have previously shown that they are activated in v-Srctransformed myoblasts and that active mutants of these GTPases impact late stages of myogenic differentiation (Gallo et al., 1999; Castellani et al., 2006) .
In addition to playing a role in v-Src-induced morphological and growth transformation (Carragher and Frame, 2002) , we have highlighted here a previously unrecognized role of calpain in inhibition of myogenic differentiation in v-Src-transformed myoblasts. Treatment of transformed myoblasts with a specific calpain inhibitor results in the rescue of myogenin expression. Since myogenin is kept transcriptionally silent in v-Srctransformed myoblasts (Falcone et al., 2003) , it is conceivable that calpain contributes to silencing of myogenin by controlling the half-life of crucial factors involved in its transcription. Simultaneous inhibition of MEK and calpain and activation of p38 appear sufficient to largely reconstitute the differentiation potential of v-Src-transformed myoblasts. We can therefore conclude that terminal differentiation of QMb-LA29 can be restored to normal levels by acting only on three major pathways.
In a recently proposed model of oncogene addiction, the abrupt inactivation of oncogenic kinases in established cell lines revealed an inherent signalling asymmetry in attenuation rates of pro-survival (ERK) and pro-apoptotic (p38) pathways eventually fostering cell death (Sharma et al., 2006) . Src myoblasts, in contrast, do not seem to have acquired a dependence upon the imposed oncogenic activity since acute deactivation of v-Src or the Ras-MEK downstream pathway resurrects activation of p38 along with rescue of their myogenic lineage signature, thus promoting terminal differentiation instead of apoptosis. In this context it should be noted that non-immortal myoblasts expressing a conditional v-Src have experienced a lifespan likely incompatible with the accumulation of genetic lesions or the selection of a particular set of signalling pathways, events otherwise frequent in established lines. This advantageous setting has facilitated the highlighting of the relevant modules relaying Src signals to the nucleus that modulate proliferation and, given the appropriate cues, expression of muscle-specific genes.
Materials and methods

Materials and antibodies
Highly purified Triton X-100 and NP-40 were from Boehringer Mannheim (Mannheim, Germany). PD98059, SB203580, LY294002 and herbimycin A inhibitors were purchased from Calbiochem (Darmstadt, Germany), U0126 from Promega (Madison, WI, USA) and ALLM from Sigma (St Louis, MO, USA). All the inhibitors were dissolved in DMSO. mAb to b-gal (D19-2F3-2) was purchased from Boehringer Mannheim, mAb to a-sarcomeric actin (5C5) was from Sigma, mAb to bromodeoxyuridine (BU-1) was from Amersham (GE Healthcare, Fairfield, CT, USA), mAb to p27/kip was from Transduction Laboratories (BD Biosciences, San Jose, CA, USA), mAb to vinculin (VIN3-24) was from the Developmental Studies Hybridoma Bank (Iowa City, IA, USA) and rabbit polyclonal antibody to p85 subunit of PI3K was from Upstate Biotechnology (Lake Placid, NY, USA). Antibodies to Ras proteins, rabbit polyclonal anti-H-Ras (C-20) (from Santa Cruz) and mAb anti-Ras (Transduction Laboratories) (cl. 18), were used for western blot and immunofluorescence, and affinity purified mAb Y13-259 (from H Paterson) was used for microinjection. Rabbit polyclonal antibodies to ERK, pERK, p38 and pp38 were from New England Biolabs (Beverly, MA, USA). mAb to hemagglutinin (HA, 12CA5) was from O Segatto, mAb to myc tag (mAb 9E10) was from Gerard Evan, mAb to skeletal a-actinin (9A2B8) and to myosin (MF20) were from D Fischman. Rabbit sera to chicken myogenin were from B Paterson and to calsequestrin from J Sutko. A rabbit serum to chicken fast skeletal muscle myosin was developed in house. Purified rabbit immunoglobulin (IgG) and tetramethyl rhodamine iso-thiocyanate (TRITC) and fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit and anti-mouse antibodies were purchased from Jackson Immunoresearch Laboratories (West Grove, PA, USA), and horseradish peroxidase-conjugated goat anti-mouse and antirabbit antibodies were from Bio-Rad (Hercules, CA, USA).
Cell cultures and viral infection
CEFs were prepared from 10-days-old SPAFAS embryos as described previously (Gallo et al., 1999) and maintained at 371C in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS, 10% tryptose phosphate broth and 1% chicken serum (referred to as GM). CEF-SR-D cells were established and propagated at 371C from primary passage cultures infected with the SR-D strain of RSV. Primary quail myoblasts were prepared and maintained as previously described (Falcone et al., 2003) . Polyclonal populations of QMb-LA29 were established from primary passage cells infected with tsLA29, a temperature-sensitive mutant of RSV, and propagated on collagen-coated dishes in GM at 351C or allowed to differentiate in F14 medium supplemented with 2% FCS (DM) at 411C as previously described (Gallo et al., 1999) . For treatment with pharmacological inhibitors, cell cultures were kept for 2 days at 351C in DM containing 50 mM PD98059, 12.5 mM U0126, 9 mM SB203580, 10 mM LY294002, 12.5-25 mM ALLM and 25 ng/ml herbimycin A. Inhibitor containing medium was renewed every day.
High-titre stocks of recombinant adenoviruses expressing bgal (by M Crescenzi), RasN17 (by L Parada), HA-tagged MKK6EE (by PL Puri) and p27 (by M Grossi) were used to infect QMb-LA29 cells. Virus expression was scored by immunofluorescence and only cultures showing a percentage of infection over 70% were further processed.
Soft agar cloning
For assaying anchorage-independent growth, 10 3 and 10 4 cells were seeded on 60 mm dishes in 0.35% agar (Difco, Sparks, MD, USA) in GM over a layer of 0.7% agar in the same medium at 351C. Inhibitors were added to both agar layers and fresh medium, containing inhibitors or DMSO, was added every 4 days. Plates were scored for colonies 2 weeks after seeding by microscopic examination.
Transient transfections and chloramphenicol acetyl transferase assay
The expression vectors used were pRSV-RasN17 (by CJ Marshall), RK5-RhoAN19 (myc-tagged RhoAN19, by A Hall), pEXVmyc-V12N17Rac1 (myc-tagged Rac1N17, by A Hall), pcDNA3-HA-MKK6EE (HA-tagged MKK6EE by PL Puri), pCMV-b (Clontech, Mountain View, CA, USA), pGreen-Lantern-1 (Life Technologies-BRL, Invitrogen Corporation, Carlsbad, CA, USA), pMCK-CAT plasmid (by EN Olson), pRSV-CAT plasmid (by B Paterson), and pSG5p85 DiSH2-N (by J Downward).
Proliferating cells were transfected with the lipofectamine reagent (Invitrogen) in serum-free Optimem (Gibco-BRL, Carlsbad, CA, USA). For transient transgene expression, 1-2 mg of plasmid DNA was transfected per 35 mm dish. After 24 h of transfection, the cells were shifted to DM for 48 h and then processed for immunofluorescence. For CAT assays, QMb-LA29 at 351C in GM were co-transfected with 0.5 mg of MCK-CAT or RSV-CAT constructs along with 1 mg of expression vectors for GFP or MKK6EE per 35 mm dish. p-CMVb (0.2 mg) was added to each DNA mixture to normalize for transfection efficiency. After 24 h, QMb-LA29 were shifted to DM for 48 h. The amount of CAT enzyme was assayed in total cell extracts by using a CAT ELISA assay (Roche Applied Science, Mannheim, Germany). b-Gal activity was assayed using the chlorophenol red-b-D-galactopyranoside (Roche Applied Science) substrate. CAT activity was calculated as a ratio of MCK-CATover RSV-CAT-expressed protein (Falcone et al., 2003) .
Microinjection and BrdU incorporation CEF and CEF-SR-D kept in low serum medium (DMEM containing 0.5% FCS) for 24 h were injected with affinity purified rabbit IgG (2 mg/ml) or a mixture (1:1) of rabbit IgG and affinity purified mAb Y13-259 (2.2 mg/ml) in phosphatebuffered saline (PBS), using an Eppendorf Transjector 5246 apparatus equipped with Eppendorf Femtotip capillaries. Following microinjection, cells were labelled with BrdU for 20 h and then processed for immunofluorescence with antiBrdU and anti-rabbit antibodies to identify microinjected cells. In each experiment, 100-200 cells for each condition were injected. For proliferation assay, transfected and untransfected cells were maintained in low serum medium for 24 h, treated with the indicated inhibitors, and labelled with BrdU for 20 h.
Cell extracts and western blot analysis
Cells were rinsed with PBS containing 0.5 mM orthovanadate and lysed in radioimmunoprecipitation assay buffer supplemented with a cocktail of protease inhibitors as previously described (Gallo et al., 1999) . Equal amounts of total extracts were resolved by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and western blots were carried out using horseradish peroxidase-conjugated goat anti-rabbit and anti-mouse antibodies and revealed with a chemiluminescence detection system by Pierce (Rockford, IL, USA).
Ras activation assay
Levels of Ras-GTP were measured by affinity precipitation using GST-Raf-binding domain. Cells were lysed in 10% glycerol, 1% NP40, 100 mM NaCl, 10 mM MgCl 2 , 50 mM Tris pH 7.4, 250 mM phenylmethylsulphonylfluoride, 10 mg/ml leupeptin and 10 mg/ml aprotinin). Cleared lysates (2 mg) were incubated with 30 mg of GST-RBD beads at 41C for 45 min. Precipitated proteins were resolved on 15% SDS-PAGE, blotted onto a polyvinylidene difluoride membrane (Roche Applied Science) and detected using antibodies to Ras.
Immunofluorescence analysis
Cultures were routinely fixed with 4% paraformaldehyde, permeabilized with 0.25% Triton X-100 in PBS, and processed as previously described (Castellani et al., 1995) . For labelling with mAb MF20, cells were fixed and permeabilized with 70% ethanol, 3.7% formaldehyde and 5% acetic acid. Samples were examined with an Olympus microscope. Images were recorded on a CCD camera and processed using a DeltaSystem and Adobe Photoshop software.
